For instance, by dual targeting IL-6 and CD40, Yang et al. showed that they could reverse TAMs-mediated tumor immunosuppression and sensitize the glioblastoma tumor to immune checkpoint inhibitors (anti-PD1 and anti-CTLA-4) in mouse tumor models[118]. The gene discussed is CTLA4; the disease is neoplasm.